FDA recall, , Moderate risk
Apotex Desmopressin Nasal Spray
Desmopressin Nasal Spray has defective bottle caps with dislodged or missing liners.
Summary by Recall Canary from the FDA notice
What happened
Apotex Corp. of Weston, Florida, began a recall of Desmopressin Nasal Spray, USP, 10 mcg/0.1 mL, 5 mL bottle (50 doses), Rx only, on April 8, 2026, due to a defect in a batch of bottle caps involving dislodged or missing cap liners. The product was distributed nationwide in the U.S.A. The recall was added to the FDA's Enforcement Report on April 16, 2026, and was classified by the FDA on May 1, 2026.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is your bottle affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Desmopressin Nasal Spray, USP, 10 mcg/0.1 mL, 5 mL bottle
- NDC
- 60505-0815-0
- Lot code
- VM4231
Recall details
- Company began the recall
- Sold in
U.S.A. Nationwide
- Company
- Apotex Corp.Weston, Florida
- Hazard
- Packaging defect
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 98736
- Recall number
- D-0510-2026
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report
In FDA's weekly enforcement report
Listed on Recall Canary
Classified by FDA
Summary updated
